Technology ID
TAB-3512
Amido compounds as RORgt Modulators for the Treatment of Th17-related Autoimmune Diseases
E-Numbers
E-287-2011-0
Lead Inventor
Littman, Daniel (New York University School of Medicine)
Co-Inventors
Huang, Wenwei (National Human Genome Research Institute (NIH/NHGRI))
Huang, Ruili (National Human Genome Research Institute (NIH/NHGRI))
Englund, Erika (NCATS)
Huh, Jun (New York University Medical Center)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Immunology
Geriatrics
Endocrinology
Dental
Cardiology
Lead IC
NCATS
ICs
NCATS
This technology includes a series of diphenylpropanamides as potent and selective RORgt inhibitors for the treatment of Th17-related autoimmune diseases. The retinoic acid-related orphan receptor RORgt plays an important role in the differentiation of thymocytes, lymphoid tissue inducer cells, and inflammatory T helper-expressing interleukin 17a (Th17) cells. Small molecule RORgt inhibitors may provide means to regulate Th17 mediated immune response.
Commercial Applications
Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases.
Competitive Advantages
This invention may offer novel therapeutics for the treatment of Th17 autoimmune diseases.
Licensing Contact: